Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Share Price Volatility

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
4.43    0.00 (0.00%)
Bid:
4.33
Ask:
4.995
Spread: 0.665 (15.358%)
Market Cap: £27.64m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Share Price Volatility

11 Dec 2019 12:49

RNS Number : 5515W
Immupharma PLC
11 December 2019
 

11 December 2019

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

SHARE PRICE VOLATILITY

 

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising. The Board can confirm that the Company is adequately funded and has no intention of raising funds.

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

 

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBDBDDLSBBGCB
12345678910
Date   Source Headline
4th Jun 20267:10 amRNS-RIncanthera plc – Corporate Update & Board Changes
2nd Jun 20267:00 amRNSNotice of AGM & Annual Report & Accounts
27th May 20267:00 amRNSFinal Results
5th May 20267:00 amRNSIMM initiatesIND-Enabling Program for Kapiglucagon
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNS-RChairman’s Open Letter to Shareholders
7th Apr 202611:45 amRNSResult of General Meeting and TVR
27th Mar 20267:00 amRNSP140 Program Update
23rd Mar 20267:00 amRNSResult of WRAP Retail Offer and TVR
19th Mar 20269:00 amRNSPublication of Circular
18th Mar 20267:00 amRNS-R‘Investor Meet Company’ presentation on 20 March
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
6th Jan 20264:11 pmRNSHolding(s) in Company
6th Jan 20267:00 amRNS-RAttending JPMorgan Conference & Biotech Showcase
24th Nov 20257:00 amRNSCorporate Update
4th Nov 20257:00 amRNSHolding(s) in Company
27th Oct 20257:00 amRNS-RIMMUPHARMA ATTENDING BIO-EUROPE
23rd Oct 20257:00 amRNSLaunch of Website; Corporate Update
13th Oct 20257:00 amRNSAppointment of Independent Non-Executive Director
6th Oct 20253:22 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSExercise of Warrants
11th Sep 20257:00 amRNSExercise of Warrants
1st Sep 20252:12 pmRNSAppointments of CSO and Head of R&D
1st Sep 20251:20 pmRNSImmuPharma Files New Patent Application for P140:
20th Aug 20251:36 pmRNSHolding(s) in Company
6th Aug 20257:00 amRNSInterim Results
12th Jun 202512:51 pmRNSResult of AGM
27th May 20253:13 pmRNSHolding(s) in Company
20th May 20257:00 amRNSNotice of AGM
19th May 20257:00 amRNSFinal Results
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
14th Mar 20257:00 amRNS-RIMM attending Bio-Europe Spring 17-19 March,Milan
13th Mar 20257:00 amRNSImmuPharma proves unique Mechanism of Action-P140
21st Feb 202511:36 amRNSHolding(s) in Company
13th Feb 20257:00 amRNS£2.91m fundraising; related party transactions
28th Jan 202512:57 pmRNSResponse to Share Price Movement
9th Jan 20257:00 amRNSBreakthrough Findings into Autoimmune Diseases
23rd Dec 20247:00 amRNSChange of Auditor
10th Dec 20242:36 pmRNSHolding(s) in Company
4th Dec 20247:00 amRNSAppointment of Company Secretary
9th Sep 20247:01 amRNSExtension of Warrants in Incanthera to 31 Mar 2025
9th Sep 20247:00 amRNSHalf-year Report
6th Aug 20241:41 pmRNSHolding(s) in Company
28th Jun 202412:17 pmRNSResult of AGM
6th Jun 20244:20 pmRNSHolding(s) in Company
5th Jun 20242:01 pmRNSNotice of AGM & Annual Report & Accounts
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
SML
Strategic Minerals
LSE
-1.02%
BRSC
BlackRock Smaller Companies Trust PLC
LSE
0.15%
HOT
Henderson Opportunity Trust
LSE
0.00%
UEM
Utilico Emerging Markets
LSE
-1.06%
BMPG
BMPG.L
LSE
0.00%
Trending
AVCT
Avacta Group
LSE
2.86%
ALRT
Defence Holdings
LSE
21.43%
PREM
Premier African Minerals
LSE
11.90%
GST
GSTechnologies
LSE
8.11%
PANR
Pantheon Resources plc
LSE
-1.19%